Deal profile | Gadens advises 4DMedical on successful acquisition of US medtech company, Imbio and its accompanying institutional placement

Gadens has advised 4DMedical Limited (4DMedical) on the acquisition US based Imbio Inc. Imbio is a recognised leader in lung and heart artificial intelligence (AI) driven technology and medical imaging. Imbio expands 4DMedical’s product offering by incorporating Imbio’s highly complementary suite of diagnostic products to help clinicians around the globe detect disease earlier, and make more robust diagnoses.

Gadens advised on all local aspects of the acquisition as well as the adjoining ~$35m capital raise.

Gadens is delighted to continue to support 4DMedical on their exciting growth journey having been successfully listed on the Australian Securities Exchange (ASX) in 2020.

Lead partner, James Beckley, said: “Alongside our US colleagues at Faegre Drinker Biddle & Reath, we were delighted to have again advised an ever determined and hard-working 4D team, to get this deal completed on an ambitious timetable. The acquisition becomes the cornerstone of 4DMedical ‘owning the lung’ and we’re excited about what the next 12 months has in store for the company.”  

Practice groups: Corporate/ECM

Value: >AU$50m

Key team members: Gadens partner James Beckley led on the acquisition with partner Jol Rogers advising on the accompanying institutional placement. The team was also supported by Peter Poulos (Partner), senior associates Gary Lim and Kaleb Cox, and lawyers Eylem Onal and Oma Murad.